AtriCure, Inc. (ATRC)
ATRCNASDAQ-GMMedical/Dental Instruments
$55.44
-2.34 (-4.05%) today
Regular session, Nov 10, 2:32 PM ET
- Market cap
- $2.82bn
- P/E
- 135.2
- EPS, last 4 quarters
- $0.4100
- Dividend yield
- –
- Day range
- $54.74 to $57.49
- 52-week range
- $25.36 to $66.02
- Average volume
- 1.13m
- Previous close
- $57.78
Analysts
8 coveringBuy6 buy, 2 hold, 0 sell
Targets a year out average $66.00, +19.0% from here
Earnings
next estimate $0.0800Next report
Dec 2025
+400.0%
Mar 2026
+100.0%
Jun 2026
+500.0%
Sep 2026
+1600.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $140.50m | $141.25m | $153.60m | $154.45m |
| Gross profit | $105.34m | $109.31m | $118.63m | $119.35m |
| Operating income | $2.49m | $526.0k | $9.66m | $4.35m |
| Net income | $1.76m | $108.0k | $8.96m | $4.06m |
Last four quarters: revenue $589.80m, margin 2.5%, free cash flow $52.94m
News
8 latest- AtriCure (ATRC) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- What AtriCure (ATRC) Said on Its Q3 Earnings CallMarketBeat · 7 days ago
- AtriCure, Inc. Reports Third Quarter 2026 Financial ResultsFintel · 7 days ago
- Compared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key MetricsZacks · 7 days ago
- AtriCure (ATRC) Beats Q3 Earnings and Revenue EstimatesZacks · 7 days ago
- Biotech Stocks At 52-Week Highs - TKNO, MRNA, ATRC, ILMN RTTNews · Sep 24, 2026
- Biotech Stocks At 52-Week Highs - NUTX +8%, IOVA +7%, ATRC, CNC, CON RTTNews · Sep 15, 2026
- Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?Zacks · Sep 14, 2026
The company
AtriCure, Inc . provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure's Isolator Synergy Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE and cryoXT probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- atricure.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.